Recent estimates indicate that one in every 10 people is affected by an autoimmune disease.
Autoimmune diseases occur when the normal function of the immune system mistakenly attacks normal and healthy cells within the body; examples of autoimmune diseases include rheumatoid arthritis, type 1 diabetes, and lupus. Currently, there are over 80 known types of autoimmune disease.
Because of their proliferation and differentiation ability, mesenchymal stem cells (MSCs) have increasingly drawn interest from the research community as a potential option for the treatment of autoimmune diseases.
In this study, Zeng et al. evaluate the efficacy and safety of MSC transplantation in the treatment of autoimmune diseases. Specifically, this review included a total of 18 RCTs involving rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), inflammatory bowel disease (IBS), ankylosing spondylitis (AS), and multiple sclerosis (MS).
Reviewing the therapeutic effects of MSCs on each of the diseases, the authors found that with the exception of MS, transplantation of MSCs may improve clinical symptoms and clinical efficacy of these autoimmune diseases. However, the authors also point out that MSCs appear to produce certain specific effects on different autoimmune diseases.
Although no obvious adverse events resulting from MSC transplantation were reported or observed during these studies, and while MSCs appear to have certain effects on different autoimmune diseases, the authors conclude that this review provides relevant evidence for the design of future clinical trials specifically assessing MSC cell source, dosage, route of drug administration, and intervention in the most ideal disease state when treating this group of diseases.
Source: “Efficacy and Safety of Mesenchymal Stem Cell Transplantation in ….” https://www.hindawi.com/journals/sci/2022/9463314/.
St. Petersburg, Florida
